Aaron Rosenberg Sells 1,157 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CFO Aaron Rosenberg sold 1,157 shares of BeOne Medicines stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $312.71, for a total value of $361,805.47. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Aaron Rosenberg also recently made the following trade(s):

• On Thursday, June 11th, Aaron Rosenberg sold 631 shares of BeOne Medicines stock. The shares were sold at an average price of $257.74, for a total value of $162,633.94.

BeOne Medicines Price Performance

NASDAQ ONC opened at $329.80 on Friday. The business has a 50 day simple moving average of $295.31 and a 200 day simple moving average of $308.62. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $253.95 and a 52-week high of $385.22. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The stock has a market cap of $36.19 billion, a price-to-earnings ratio of 58.06 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.85%. The firm had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. Analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 earnings per share for the current fiscal year.

Institutional Trading of BeOne Medicines

A number of large investors have recently added to or reduced their stakes in the company. EFG International AG acquired a new position in shares of BeOne Medicines in the fourth quarter valued at $25,000. Leonteq Securities AG acquired a new stake in shares of BeOne Medicines during the 4th quarter worth about $35,000. Daiwa Securities Group Inc. acquired a new stake in shares of BeOne Medicines during the 2nd quarter worth about $35,000. CWM LLC boosted its holdings in shares of BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the period. Finally, Group One Trading LLC bought a new stake in shares of BeOne Medicines during the 4th quarter worth about $61,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Morgan Stanley reaffirmed an “overweight” rating on shares of BeOne Medicines in a research report on Thursday. Truist Financial increased their target price on BeOne Medicines from $416.00 to $418.00 and gave the stock a “buy” rating in a report on Thursday. Guggenheim boosted their price target on BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a report on Thursday. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 18th. Finally, Royal Bank Of Canada decreased their price objective on BeOne Medicines from $451.00 to $450.00 and set an “outperform” rating for the company in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, BeOne Medicines currently has an average rating of “Moderate Buy” and a consensus price target of $400.00.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Strong Q2 performance: BeOne reported earnings of $2.05 per share, exceeding the $1.40 consensus estimate by $0.65. Revenue reached $1.71 billion, above the $1.66 billion forecast, with quarterly revenue reportedly up 30% year over year. The substantial earnings beat supports the view that the company’s oncology portfolio is generating stronger profitability than expected. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook raised: Management now expects full-year revenue of $6.6 billion to $6.8 billion, above the approximately $6.5 billion analyst consensus. The improved outlook indicates continued commercial momentum and gives investors greater confidence in the company’s growth trajectory. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analysts raised targets: TD Cowen increased its price target to $454 and assigned a Buy rating. Guggenheim raised its target to $430, Truist to $418 and Citizens JMP to $405, all with favorable ratings. These revisions suggest analysts see additional upside following the earnings report. Analyst price-target updates
• Neutral Sentiment: RBC remains bullish despite a small target reduction: Royal Bank of Canada lowered its target marginally to $450 but maintained an Outperform rating, signaling that the change does not materially weaken its investment view. RBC analyst update
• Neutral Sentiment: CFO stock sale: CFO Aaron Rosenberg sold 1,157 shares worth approximately $362,000 to cover tax withholding tied to vested equity awards. Because the transaction was tax-related rather than a discretionary sale, it is unlikely to materially affect sentiment. BeOne Medicines SEC insider filing

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.